Retinoid X receptor alpha (RXRa) and its N-terminally truncated version, tRXRa, are widely implicated in cancer development and represent intriguing targets for cancer prevention and treatment. Successful manipulation of RXRa and tRXRa requires the identification of their modulators that could produce therapeutic effects. Here, we report that a class of nitrostyrene derivatives bind to RXRa by a unique mechanism, of which the nitro group of nitrostyrene derivatives and Cys432 of RXRa are required for binding. The binding results in the potent activation of Gal4-DBD-RXRa-LBD transactivation. However, the binding inhibits the transactivation of RXRa homodimer, which might be due to the distinct conformation of RXRa homodimer induced by these nitrostyrene derivatives. Two RXRa point mutants with Cys432 substituted with Tyr and Trp, respectively, could mimic the bindings of two nitrostyrene derivatives and have the ability of autotransactivation. In studying the functional consequences of the binding, we show that these nitrostyrene derivatives could potently inhibit the TNFa/NFkB signaling pathway in a tRXRadependent manner. tRXRa promotes TNFa-induced NF-kB activation through its interaction with TRAF2 and enhances TNFainduced ubiquitination of RIP1, which is strongly inhibited by nitrostyrene derivatives. The inhibition of TNFa-induced NF-kB activation results in the synergistic effect of the combination of nitrostyrene derivatives and TNFa on the induction of cancer cell apoptosis. Together, our results show a new class of RXRa modulators that induce apoptosis of cancer cells through their unique binding mode and new mechanism of action.
Introduction
Retinoid X receptor alpha (RXRa) plays pleiotropic roles in the biologic and pathologic processes (1, 2) . Dysfunctions of RXRa are implicated in a number of diseases, such as cancer. For examples, abnormal changes of RXRa expressions or modifications are associated with the development of prostate, skin, liver, and colon cancers (3) (4) (5) (6) . Like other nuclear receptors, RXRa binds to its responsive elements to regulate gene transcription in the nucleus (7) . Recently, accumulating evidence demonstrates the nongenomic actions of RXRa. For example, some apoptotic stimuli induce RXRa and Nur77 translocating from the nucleus to the cytoplasm, where they execute proapoptotic effects via association of Bcl-2 and transition of Bcl-2 from an anti-to a proapoptotic molecule (8, 9) . RXR was also shown to bind to the G protein Gq in a ligand-dependent manner and impair Gq-mediated Rac activation and intracellular calcium release (10) .
Several small molecules have been identified as endogenous RXRa ligands, such as 9-cis-retinoic acid (9-cis-RA) and docosahexaenoic acid, and many synthetic compounds also bind to RXRa selectively and exhibit RXRa-dependent effects (11) . In general, RXRa ligands are constituted of three building blocks, the hydrophobic ring, a central polyene linker, and a polar motif such as carboxyl group (12) . The ionic interactions and hydrogen bonds formed between the carboxyl group of 9-cis-RA and Arg316 residue of RXRa are essential for the binding of 9-cis-RA to the ligand-binding pocket (LBP) of RXRa (13) . Recently, some nonclassical ligands have been reported to bind to RXRa in different manners. K-8008, a derivative of sulindac, binds to the surface of RXRa (14) . CF31, bigelovin, and magnolol do not require Arg316 for binding to the LBP of RXRa (15) (16) (17) . Thus, RXRa is subjected to modulation by diverse molecules through different mechanisms.
TNFa displays a variety of physiologic activities in a cell-and tissue context-dependent manner. It stimulates the NF-kB and Akt pathways to enhance cell survival, whereas in certain contexts, it provokes apoptotic events by activating the caspase-8-mediated death pathway (18, 19) . Recently, we reported that the nongenomic action of an N-terminally truncated RXRa (tRXRa) could play a role in the crosstalk with TNFa signaling (15, 20) . tRXRa produced by proteolytic cleavage of full-length RXRa is highly expressed in a variety of tumor cells and tissues (21) . In response to TNFa, tRXRa interacts with the p85a regulatory subunit of PI3K, followed by the activation of Akt to promote tumor cell growth. However, whether tRXRa could crosstalk with other TNFa-dependent signal pathways and whether small molecules could modulate its activities remain unknown.
Nitrostyrene derivatives have been identified as potent anticancer agents (22, 23) , whereas the underlying mechanisms are still elusive. In the current study, we demonstrated that nitrostyrene derivatives (Z compounds) could inhibit the TNFa/NFkB signaling pathway by binding to tRXRa and blocking the interactions of tRXRa with TRAF2, leading to TNFa-and tRXRadependent apoptosis of cancer cells.
Materials and Methods

Reagents and antibodies
Antibodies for RXR (sc-774), PARP-1/2 (sc-7150), c-Myc (sc-40), c-Myc (sc-789), NF-kB p65 (sc-8008), a-tubulin (sc-8035), ubiquitin (sc-9133), and cyclin D1 (sc-20044) were purchased from Santa Cruz Biotechnology; Antibodies for Flag (F1804) and b-actin (A2228), and 9-cis-RA (R4643), ATRA (R2625), dexamethasone (D1756), T0901317 (T2320), and rosiglitazone (R2408) were purchased from Sigma-Aldrich; Antibody for IkBa (ab32518) was from Abcam; antibodies for cleaved caspase-8 (#9496), p-IKKa/b (#2078), TRAF2 (#4712), and p62 (#5114) were from Cell Signaling Technology; TNFa (210-TA) was from R&D Systems; RIP1 antibody (551041) was from BD Biosciences. Propyl pyrazole triol (1426) was from Tocris Bioscience; [ 3 H]9-cis-RA was obtained from Amersham; Z compounds were dissolved in ddH 2 O or dimethylsulfoxide respectively.
Cell culture
Cell lines were passaged for fewer than 4 months after resuscitation and were used at the fifth through tenth passage in culture for this study. MCF-7 human breast cancer and HEK293T human embryonic kidney cells were cultured in DMEM (Thermo Fisher Scientific) supplemented with 10% FBS (Life Technologies) in a humidified atmosphere containing 5% CO 2 at 37 C. Cell transfections were carried out by using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions.
Mammalian one-hybrid assay
HEK293T cells were cotransfected with pG5-luc reporter (Promega) together with the plasmids encoding different NR-LBDs fused with the DNA-binding domain of Gal4. One day after transfection, cells were treated with DMSO, Z compounds, or ligands specific for each nuclear receptor. After 12 hours, cells were lysed by passive lysis buffer. Firefly and Renilla luciferase activities were quantitated using the Dual-Luciferase Reporter Assay System (Promega, E1960). Transfection and expression efficiency was normalized to Renilla luciferase activity.
Protein expression and purification
The human RXRa-LBD (223-462) was cloned as an N-terminal histidine-tagged fusion protein in pET15b expression vector and overproduced in Escherichia coli BL21 DE3 strain. Briefly, cells were harvested and sonicated, and the extract was incubated with the His60 Ni Superflow resin. The protein-resin complexes were washed and eluted with imidazole. The eluent was collected and concentrated to 5 mg/mL for subsequent trials.
Ligand competition assay
RXRa-LBD protein was incubated with different concentrations of unlabeled 9-cis-RA, Z compounds, or their derivatives in 200 mL of binding buffer [0.15 mol/L KCl, 10 mmol/L Tris-HCl (pH 7.4), 8% glycerol, and 0.5% CHAPS detergent] at 4 C for 1 hour. [ 3 H]9-cis-RA was added to the tubes to a final concentration of 7.5 nmol/L and a final volume of 300 mL and incubated overnight at 4 C. The RXRa-LBD was captured by nickel-coated beads. Bound [ 3 H]9-cis-RA was quantitated by liquid scintillation counting (20) .
Surface plasmon resonance
The binding kinetics between RXRa-LBD and compounds was analyzed at 25 C on a BIAcore T200 machine with CM5 chips (GE Healthcare). RXRa-LBD (20 mg/mL in 10 mmol/L sodium acetate, pH 5) was immobilized on the CM5 chip using amine coupling procedures according to the manufacturer's instructions. A serial concentration of Z compounds ranging from 1 to 10 mmol/L were used for the experiment at a flow rate of 20 mL/minute. When the data collection was finished in each cycle, the sensor surface was regenerated with Glycine-HCl (10 mmol/L, pH 2.5). Sensorgrams were fit globally with BIAcore T200 analysis using 1:1 Langmuir binding mode.
Isothermal titration calorimetry
The thermodynamic properties of compounds binding to RXRa-LBD were determined using a VP-ITC titration calorimeter (MicroCal) in phosphate buffer at 25 C. The sample cell was filled with His-RXRa-LBD (50 mmol/L in 25mmol/L Tris-HCl, pH 7.5, 150 mmol/L NaCl, 0.1% DMSO). The compounds were diluted to a concentration of 1 mmol/L in the same buffer. The injection volumes were 2 mL each with injection time 4 seconds and a 120 second delay between each injection. The heat of dilution was obtained by injecting compounds into the same buffer and subtracted from the reaction before the fitting process.
Immunostaining, immunoblotting, coimmunoprecipitation assays, and GST pulldown
Immunostaining, immunoblotting, coimmunoprecipitation, and GST pulldown assays were performed as described (8, 9) .
Size-exclusion chromatography assay
Size-exclusion chromatography assays were performed on an € AktaPurifier system equipped with a HiLoad 16/600 Superdex 200 pg column (GE Healthcare). The column was pre-equilibrated with buffer [50 mmol/L sodium phosphate (pH 7.2), 150 mmol/L NaCl) and RXRa-LBD protein was run at a flow rate of 1 mL/minute.
MCF-7 xenografts
Nude mice (BALB/c, 4-5 weeks old) were injected subcutaneously with 100 mL MCF-7 cells (2 Â 10 6 ). For drug treatment, mice were administered with Z-12 (30 mg/kg) diluted in Tween80 intragastrically once a day and TNFa (120 Â 10 4 U/kg) diluted in PBS plus 3 mg/mL bovine serum albumin intratumorally every 2 days alone or in combination after 6 days of transplantation. Body weight and tumor sizes were measured every 2 days. Mice were killed after drug treatment and tumors were removed for various assessments. All manipulations involving live mice were approved by the Animal Care and Use Committee of Xiamen University (Xiamen, Fujian, China).
Statistical analysis
Data were expressed as mean AE SD. Each assay was repeated in triplicate in three independent experiments. The statistical significance of the differences among the means of several groups was determined using the Student t test.
Results
Z compounds selectively regulate RXRa transactivation
We performed mammalian one-hybrid assay to screen for RXRa modulators using our in-house chemical library, and unexpectedly found that a nitrostyrene derivative (Z-1) selectively activated the transcriptional activity of the fusion protein Gal4-DBD-RXRa-LBD but not Gal4-DBD-RARa-LBD or Gal4-DBD-ERa-LBD ( Fig. 1A and B ). We then designed and synthesized a series of Z-1 derivatives designated as Z-2 to Z-12 ( Supplementary Table S1 ). Two optimized derivatives, Z-10 and Z-12, dose dependently activated RXRa transactivation, of which Z-10 and Z-12 at a concentration of 10 mmol/L reached to similar and about 50% activity of 0.1 mmol/L 9-cis-RA, respectively ( Fig. 1A and C and Supplementary Fig. S1A ). Interestingly, Z-11, which is different from Z-10 only in the position of the nitrovinyl group on naphthalene, was unable to activate RXRa ( Fig. 1A and C), demonstrating a strict requirement of Z compound' structure for activating RXRa. In contrast to the benzene group of Z-1, the naphthalene group of Z-10 and anthracene group of Z-12 are larger aromatic groups, suggesting that larger groups induced a more favorable RXRa conformation for transactivation. The effect of Z-10 and Z-12 on RXRa transactivation was highly selective, as neither of them significantly activated the chimeric reporters of other nuclear receptors, including RARa, RARg, ERa, GR, LXRa, and PPARg ( Fig. 1D and Supplementary Fig. S1B ).
Nitro group is crucial for Z-10 and Z-12 binding and regulating RXRa transactivation
The regulation of RXRa transactivation by Z-10 and Z-12 prompted us to study their binding to RXRa protein in vitro by ligand competition assay. Similar to unlabeled 9-cis-RA, Z-10 and Z-12 dose dependently competed with [ 3 H]-labeled 9-cis-RA for binding to RXRa-LBD, with IC 50 at 0.28 and 0.81 mmol/L, respectively. Interestingly, although Z-11 did not activate RXRa, it exhibited similar competition ability as Z-10 and Z-12 with an IC 50 at 0.33 mmol/L, implying that Z-11 bound to RXRa but induced a distinct conformation of RXRa ( Fig. 2A ). Our surface plasmon resonance (SPR)-based assay indicated that Z-10 and Z-12 dose dependently bound to RXRa-LBD with K d values of 5.74 and 1.95 mmol/L, respectively (Fig. 2B ). The K d value of Z-10 binding to RXRa-LBD measured by isothermal titration calorimetry (ITC)-based assay was 2.98 mmol/L, which was in the same order of magnitude as that measured by SPR assay (Fig. 2C ). Moreover, our assays based on differential scanning calorimetry (DSC) demonstrated that the T m values of RXRa-LBD protein were shifted higher by Z-10, Z-11, and Z-12 (Supplementary Fig. S2A ). Together, these data indicate that Z-10, Z-11, and Z-12 could bind to RXRa directly.
Different from classical RXRa ligands, Z serial compounds do not possess a carboxyl group but instead a nitro group. To examine the role of the nitro group, it was replaced with a carboxyl group ( Supplementary Table S2 ). Ligand competition assay demonstrated that all the carboxyl derivatives (Z-10-1, Z-11-1, and Z-12-1) failed to displace [ 3 H]9-cis-RA from binding to RXRa-LBD ( Fig. 2A ). Similar results were determined by our DSC and ITC assays ( Supplementary Fig. S2A and S2B ). Consistently, the carboxyl derivatives were incapable of activating Gal4-DBD-RXRa-LBD transcriptional activity ( Fig. 2D ). We also replaced the nitro group of Z-10 with other functional groups, including formyl, hydroxylamine, amine, and cyano ( Supplementary  Table S3 ), and none of the derivatives (Z-10-2, -3, -4 and -5) could bind to or activate RXRa ( Fig. 2E and Supplementary  Fig. S2B and S2C ). Taken together, these results demonstrate that the nitro group is essential for Z compounds binding to RXRa and regulating RXRa transactivation.
Z compounds bind to RXRa in a unique manner and induce distinct RXRa conformations
To investigate the effects of Z compounds on RXRa homodimer transactivation, we performed reporter assay using RXREluciferase reporter known to bind with RXRa homodimers (24) . To our surprise, both Z-10 and Z-12 failed to induce the transactivation of RXRa homodimer. Moreover, they inhibited 9-cis-RA-induced transactivation (Fig. 3A ). We then examined the effects of Z compounds on RXRa homodimer formation. The purified RXRa-LBD protein exhibited two bands on the native gel, of which the upper and lower bands represented homotetramers and homodimers, respectively. Similar to 9-cis-RA, the incubation of RXRa-LBD protein with Z-10 and Z-12 induced homodimer formation, accompanying with the reduction of tetramers. However, the homodimers induced by Z-10 and Z-12 migrated slightly slower than the control and 9-cis-RA-induced dimers ( Fig. 3B and Supplementary Fig. S3A ). Thus, Z-10 and Z-12 could induce distinct conformations of RXRa homodimers, which was also demonstrated by our assay of size-exclusion chromatography (Fig. 3C ). This provided a possible explanation for the inability of Z-10 and Z-12 to activate RXRa homodimer despite their ability to induce homodimer formation. Unlike Z-10 and Z-12, Z-11 induced higher levels of RXRa-LBD oligomerization ( Fig. 3B and Supplementary Fig. S3A ), consisting with its inability of activating RXRa transactivation even binding to RXRa. As expected, the carboxyl derivatives did not show any effect on the formation of RXRa-LBD tetramer and dimer ( Fig. 3B and Supplementary  Fig. S3A ). The distinct conformations induced by Z-10 and Z-12 were also illustrated by the different patterns of the cleaved RXRa-LBD fragments produced by limited proteolysis in the presence of Z-10, Z-12, DMSO, and 9-cis-RA ( Supplementary  Fig. S3B ).
It was imagined that the distinct RXRa conformations induced by Z compounds resulted from their unique binding mode. Cocrystallography and mutagenesis assays have revealed that Arg316 in the LBP of RXRa is essential for 9-cis-RA binding (13, 15) . We therefore examined the role of Arg316 for Z-10 and Z-12 activity by reporter assay using Gal4-DBD-RXRa-LBD/ R316E, a mutant with Arg316 substituted with Glu. While 9-cis-RA failed to activate the mutant, Z-10 and Z-12 strongly activated its transactivation ( Fig. 3D ). Consistently, Z-10 bound to RXRa-LBD/R316E protein with a K d value of 8.30 mmol/L ( Supplementary Fig. S3D ). Thus, the nitro group of Z compounds might not form ionic interactions and hydrogen bonds with Arg316, suggesting a different binding manner of Z compounds, which was further characterized using other point mutants of Gal4-DBD-RXRa-LBD ( Fig. 3E and Supplementary Fig. S3C ). 
B, Z-1 selectively activates RXRa transcriptional activity. HEK293T cells transfected with the indicated pBINDplasmids and pG5-luc were treated with 9-cis-RA (0.1 mmol/L), PPT (10 mmol/L), and Z-1 (10 mmol/L) for 12 hours. For all luciferase activity assays, Renilla luciferase values were normalized to firefly luciferase activity and plotted as relative luciferase activity. C, Z-10 and Z-12 are optimized Z-1 derivatives. HEK293T cells transfected with pBIND-RXRa-LBD and pG5-luc were treated with 9-cis-RA (0.1 mmol/L) and the indicated Z-1 derivatives (10 mmol/L). Luciferase activities were measured 12 hours after treatment and relative luciferase activity was plotted. D, Z-10 and Z-12 selectively activate RXRa transcriptional activity. HEK293T cells transfected with the indicated pBINDplasmids and pG5-luc were treated with 9-cis-RA (0.1 mmol/L), ATRA (0.1 mmol/L), PPT (10 mmol/L), dexamethasone (1 mmol/L), T09 (1mmol/L), rosiglitazone (Ros; 1 mmol/L), Z-10 (5 mmol/L), and Z-12 (5 mmol/L) for 12 hours, and luciferase activities were measured and normalized. Data shown are representative of at least three independent experiments. 9-cis-RA, 9-cis-retinoic acid; ATRA, all-trans retinoic acid; PPT, propyl pyrazole triol; T09, T0901317; RXRa, retinoid X receptor a; RARa and RARg, retinoic acid receptor a and g, respectively; ERa, estrogen receptor a; GR, glucocorticoid receptor; LXRa, liver X receptor a.
Neither 9-cis-RA nor Z compounds activated the mutants with Cys432 substituted with Gln, Trp, or Tyr. However, mutation of Cys to Ser completely incapacitated Z-10 and Z-12 but not 9-cis-RA ( Fig. 3E ). Thus, Cys432 was more essential for Z compounds than for 9-cis-RA, and the point mutation of C432S could be used to distinguish 9-cis-RA from Z compounds. Consistently, Z-10 failed to bind to RXRa-LBD/C432S, C432Q and C432W (Supplementary Fig. S3D ), demonstrating the crucial role of Cys432 for Z compounds binding. Sequence alignment of several nuclear receptors indicated that Cys432 was a unique residue in RXRa ( Supplementary Fig. S3E ), which might explain the RXRa selectivity of Z compounds. Intriguingly, substitution of Cys432 with Trp or Tyr resulted in two mutants with autoactivating ability (Fig.  3E ). Structural comparison indicated that the phenol group of Tyr and the indole group of Trp are similar to the benzyl group of Z-1 and the naphthalene group of Z-10, respectively, in both the molecular size and the spatial structure ( Fig. 3F ). Therefore, it was imagined that the two mutations could mimic the bindings of Z-1 and Z-10, which was demonstrated by our size-exclusion chromatography assay showing that the mutant RXRa-LBD/C432W could form dimer spontaneously and our native gel electropho-resis assay showing that the similar migration rate of the mutant dimer and the Z-10-induced dimer ( Fig. 3G and H) .
Z-10 and Z-12 inhibit TNFa activation of the NF-kB signaling pathway
We reported previously that K-80003, a sulindac derivative, could inhibit TNFa-induced Akt activation by preventing the interaction of tRXRa and p85a (20) . Unlike K-80003, Z-10, and Z-12 could not inhibit TNFa-induced interaction of tRXRa with p85a ( Supplementary Fig. S4A ). Instead, Z-10 dose dependently inhibited NF-kB activation by TNFa in our reporter gene assay ( Supplementary Fig. S4B ). Consistently, TNFa-induced expression of NF-kB target genes, including c-myc, cyclin D1, and p62, was inhibited by Z-10 and Z-12 (Fig. 4A ). Further analysis revealed that Z-10 and Z-12 significantly inhibited TNFa-induced p65 nuclear translocation, IkBa degradation, and IKKa/b phosphorylation (Fig. 4B, 4C and Supplementary Fig. S4C ). We next examined whether the inhibition of NF-kB activation was RXRa dependent. Compared with control siRNA, transfection of RXRa siRNA decreased the expression of both RXRa and tRXRa, which was accompanied with the impaired effect of Z compounds on TNFa-induced IkBa degradation ( Supplementary Fig. S4D ). The RXRa-dependent effect of Z compounds was also illustrated by our results showing that the inhibitory effect of Z-10 on TNFainduced IkBa degradation was stronger in MCF-7 cells expressing higher levels of RXRa and tRXRa than in H460 cells with much lower RXRa and tRXRa expression ( Fig. 4D ). We also examined whether the effect of Z compounds could be modulated by known RXRa ligands such as 9-cis-RA, CD3254 and UVI3003, which did not show apparent effects on TNFa-induced IkBa degradation ( Supplementary Fig. S4E ). When Z compounds were used together with these known RXRa ligands, the inhibitory effects of both Z-10 and Z-12 on TNFa-induced IkBa degradation was reduced (Fig. 4E ). In addition, the carboxyl derivatives, Z-10-1 and Z-12-1 incapable of binding to RXRa, did not show any effect on TNFa-induced IkBa degradation ( Supplementary  Fig. S4F ). Taken together, these data demonstrate that Z-10 and Z-12 inhibit TNFa activation of the NF-kB signaling pathway in an RXRa/tRXRa-dependent manner.
Z compounds inhibit tRXRa-mediated RIP1 ubiquitination and the interaction of TRAF2 and tRXRa
To determine the molecular mechanism by which Z compounds inhibited TNFa activation of NF-kB, we first analyzed the role of RXRa and tRXRa in this signaling pathway. Overexpression of Myc-RXRa/D80 (representing tRXRa) but not Myc-RXRa in MCF-7 cells significantly enhanced both the basal and TNFa-stimulated NF-kB transcriptional activity and IkBa degradation ( Supplementary Fig. S5A and S5B) . TRAF, the IKK Figure 3 . Z-10 and Z-12 bind RXRa in a unique manner. A, effect of Z-10 and Z-12 on 9-cis-RA-induced RXRa homodimer transactivation. HEK293T cells were cotransfected with pGL6-TA-RXRE-luciferase and Renilla luciferase together with pCMV-myc-RXRa plasmid for 24 hours. Cells were then treated with or without 9-cis-RA (0.1 mmol/L) in the presence or absence of 5 mmol/L Z-10 and Z-12 for 12 hours. Luciferase activities were measured and normalized. B, Z-10 and Z-12 induce distinct conformation of RXRa-LBD homodimer. RXRa-LBD protein (0.2 mg/mL) was incubated with DMSO, 9-cis-RA (0.5 mmol/L), or the indicated Z compounds (10 mmol/L) for 3 hours, and proteins were separated by 8% nondenaturing PAGE followed by Commassie Blue staining. C, Z-10 induces different homodimers of RXRa. RXRa-LBD proteins (2 mg/mL) incubated with DMSO or Z-10 (10 mmol/L) were analyzed by sizeexclusion chromatography assay. D and E, Cys432 but not R316 is required for Z-10 and Z-12 to induce RXRa transcriptional activity. HEK293T cells transfected with the indicated plasmids were treated with 9-cis-RA (0.1 mmol/L), Z-10 (5 mmol/L), or Z-12 (5 mmol/L). Luciferase activities were measured and normalized. F, structural comparison of Z-1 and Z-10 with tyrosine and tryptophan. G, the spontaneous formation of RXRa-LBD/C432W homodimer was analyzed by size-exclusion chromatography assay. H, the homodimers of RXRa-LBD/C432W were analyzed by nondenaturing PAGE. Data shown are representative of at least three independent experiments. upstream transducer of the TNFa/NFkB signal pathway, is an essential component in this pathway (25) . Ectopic expression of TRAF2 slightly activated NF-kB transcription and IkBa degradation, which was dramatically enhanced by transfection of Myc-RXRa/D80 but not Myc-RXRa in a dose-dependent manner ( Fig. 5A and B) . Thus, tRXRa, but not RXRa, is a positive regulator of TNFa activation of NF-kB. When TRAF2 expression was suppressed by siRNA-mediated knockdown, the effect of Z-12 on inhibiting TNFa-induced IkBa degradation was dramatically reduced, indicating the role of TRAF2 in the activity of Z compounds ( Fig. 5C ). We then determined the possibility that tRXRa interacted with TRAF2. When Flag-TRAF2 was cotransfected with either Myc-RXRa/D80 or Myc-RXRa, immunoprecipitation of Flag-TRAF2 resulted in coprecipitation of Myc-RXRa/D80 but not Myc-RXRa, which was strongly enhanced by TNFa (Fig. 5D) . Similarly, when the complex was immunoprecipitated with anti-Myc antibody, Flag-TRAF2 was detected in the immunoprecipi-tated complex when coexpressed with Myc-RXRa/D80 but not Myc-RXRa ( Supplementary Fig. S5C ). We also found that TNFa could induce the interaction of Myc-RXRa/D80 with endogenous TRAF2 ( Supplementary Fig. S5D ). The direct interaction of RXRa/D80 and TRAF2 was revealed by our GST pulldown assay ( Supplementary Fig. S5E ). Further analysis indicated that the N-terminal region of TRAF2 was responsible for binding to RXRa/D80 ( Supplementary Fig. S5F ). When the effect of Z-10 and Z-12 was analyzed, we found that treatment of cells with either of the compounds strongly inhibited TNFa-induced interaction of tRXRa with TRAF2 (Fig. 5E ). The activation of TRAF2 often leads to the ubiquitination of RIP1, which is required for the activation of NF-kB by TNFa (26, 27) . We found that RXRa/D80 could strongly promote TNFa-induced RIP1 ubiquitination, which was largely blocked by Z-10 ( Fig. 5F ). Together, tRXRa may contribute to the activation of the NF-kB pathway by TNFa through binding to TRAF2 and promoting RIP1 ubiquitination, and Z compounds may suppress tRXRa-dependent activation of the NF-kB signaling pathway through their inhibition of tRXRa/ TRAF2 complex formation.
IkBa
UVI3003 -----+ -----+ CD3254 ----+ -----+ -9-cis-RA ---+ -----+ --Z-12 --------+ + + + Z-10 --+ + + + ------
Z-10 and Z-12 induce TNFa-and tRXRa-dependent cancer cell apoptosis
We hypothesized that suppression of tRXRa activation of the NF-kB survival signaling by Z compounds may provoke the apoptotic potential of TNFa. Indeed, when cells were treated with TNFa together with either Z-10 or Z-12, a significant apoptosis of cells, indicated by PARP cleavage and nuclear fragmentation, was observed, which did not happen when cells were treated with Z-10, Z-12, or TNFa alone ( Fig. 6A and Supplementary Fig. S6A ). TNFa is known to induce caspase-8-dependent apoptosis (18) , which was also revealed by our experiment (Fig. 6A) . Treatment of cells with the general caspase inhibitor Figure 5 . Z-10 and Z-12 inhibit tRXRa-mediated TNFa activation of NF-kB. A, Myc-RXRa/D80 but not Myc-RXRa enhances TRAF2-stimulated NF-kB transactivation. MCF-7 cells were transiently transfected with NF-kB luciferase reporter and Renilla luciferase with or without Myc-RXRa/D80 and Myc-RXRa expression plasmids for 24 hours. Luciferase activities were measured and normalized. The values of y-axis were 1,000 times of relative luciferase activity. B, Myc-RXRa/D80 but not Myc-RXRa enhances TRAF2-induced downregulation of IkBa. MCF-7 cells were transfected with the indicated plasmids for 24 hours, and cell lysates were prepared and analyzed by immunoblotting. b-Actin was used as a loading control. C, suppression of TRAF2 expression impairs the inhibitory effect of Z-12 on TNFa-induced IkBa degradation. MCF-7 cells transfected with siRNA of control or TRAF2 for 36 hours were treated with Z-12 for 1 hour before exposure to TNFa (10 ng/mL) for 30 minutes. Protein expressions were analyzed by immunoblotting. D, interaction of TRAF2 with tRXRa but not RXRa. HEK293T cells were transfected with the indicated plasmids for 24 hours and then treated with TNFa (40 ng/mL) for 15 minutes. The complex formations were examined by coimmunoprecipitation using specific antibodies. E, effects of Z-10 and Z-12 on TNFa-induced formation of TRAF2/tRXRa complex. HEK293T cells were transfected with the indicated plasmids for 24 hours and then treated with Z-10 (5 mmol/L) and Z-12 (5 mmol/L) for 1 hour before exposure to TNFa (40 ng/mL) for 15 minutes. Protein interactions were analyzed by coimmunoprecipitation. F, tRXRa-induced RIP1 ubiquitination is inhibited by Z-10. MCF-7 cells transfected with or without Myc-RXRa/D80 expression plasmids were treated with Z-10 (10 mmol/L) for 1 hour before stimulation with TNFa (20 ng/mL) for 5 minutes. RIP1 ubiquitination was examined by immunoprecipitation with anti-RIP1 antibody followed by immunoblotting with antiubiquitin antibody. Data shown are representative of at least three independent experiments. IP, immunoprecipitation.
Z-VAD-FMK completely blocked the PARP cleavage induced by the combination of TNFa and Z compounds ( Supplementary Fig.  S6B ). Thus, Z compounds are able to activate the death effect of TNFa. Consistently, TNFa combination with Z-10 exhibited much stronger inhibitory effects on MCF-7 cell colony formation than either of them alone (Fig. 6B) .
In contrast to the effect of Z compounds, 9-cis-RA, CD3254 and UVI3003 showed little effect on inducing PARP cleavage in the presence of TNFa ( Supplementary Fig. S6C ). However, they were able to suppress the apoptotic effect of the combination of TNFa and Z compound ( Fig. 6C ), suggesting the involvement of RXRa in the apoptotic induction of the combination. This was first confirmed by RXRa siRNA experiments, showing that transfection of RXRa siRNA prevented PARP cleavage induced by the combination of TNFa and Z compounds ( Supplementary Fig. S6D ). In addition, the expression levels of RXRa and tRXRa in SW480, H460, and MCF-7 cells were directly correlated to the apoptotic status of the cells treated by TNFa/Z-10 combination (Fig. 6D ). Figure 6 . Z compounds and TNFa synergistically induce cancer cell apoptosis in a tRXRa-dependent manner. A, synergistic induction of PARP cleavage by TNFa combination with Z-10 or Z-12. MCF-7 cells cultured in medium with 1% FBS were treated with Z-10 (7.5 mmol/L), Z-12 (5 mmol/L), and/or TNFa (10 ng/mL) for 9 hours. Immunoblotting was applied to examine PARP cleavage. B, effect of Z-10 and TNFa on clonogenic survival of MCF-7 cells. C, effect of RXRa ligands on the synergistic induction of PARP cleavage by TNFa combination with Z-10 or Z-12. MCF-7 cells pretreated with 9-cis-RA (0.1 mmol/L), CD3254 (0.1 mmol/L), or UVI3003 (1 mmol/L) for 1 hour were treated with TNFa (10 ng/mL) and Z-10 (7.5 mmol/L), or Z-12 (5 mmol/L) for 9 hours. D, correlation of the synergistic apoptotic induction of TNFa/Z-10 and RXRa/tRXRa protein levels. Cells were treated with Z-10 (7.5 mmol/L) and TNFa (10 ng/mL) for the indicated time. E, effect of stable expression of RXRa and tRXRa on the synergistic apoptotic effect of TNFa/Z-10. Cells were treated with TNFa (10 ng/mL) and/or Z-10 (7.5 mmol/L) for 9 hours. F and G, TRAF2 rescues MCF-7 apoptosis induced by Z-10 and TNFa. MCF-7 cells transfected with Flag-TRAF2 (F) or dominant-negative TRAF2 (Flag-dn-TRAF2; G) were treated with TNFa (10 ng/mL) and/or Z-10 (7.5 mmol/L). For comparison, Z-10-1 and Z-12-1 did not show any synergistic proapoptotic effects when used together with TNFa (Supplementary Fig. S6E ). To further distinguish the role of RXRa and tRXRa, we stably transfected RXRa and RXRa/D80 in MCF-7 cells and examined the apoptosis of the resulting stable cell lines treated by the TNFa/Z compound combination. Compared with the parental MCF-7 cells, RXRa/D80 but not RXRa stable cell line showed increased apoptosis when treated with either TNFa/Z-10 or TNFa/Z-12 combination ( Fig. 6E and Supplementary Fig. S6F) . Similarly, we observed RXRa/D80-, but not RXRadependent nuclear fragments induced by the TNFa/Z-10 combination ( Supplementary Fig. S6G ). Together, these data demonstrate that the combination of TNFa and Z compounds induces a tRXRa-dependent apoptosis of MCF-7 cancer cells. When Flag-TRAF2 was overexpressed in MCF-7 cells, the synergistic effects of TNFa and Z-10 on inducing PARP cleavage were largely blocked (Fig. 6F) . In contrast, overexpression of dominant-negative TRAF2 (dnTRAF2) stimulated TNFainduced PARP cleavage, which was not enhanced by Z-10 ( Fig. 6G) . These data suggested that the inhibition of TNFa/ NFkB signaling by Z compounds led to the activation of the TNFa apoptotic pathway, providing an explanation for the synergistic proapoptotic effects of the combination. We further evaluated whether Z compounds alone or combination with TNFa inhibited MCF-7 cell growth in vivo. After subcutaneous injection of MCF-7 cells, we treated mice with vehicle, Z-12, TNFa, or TNFa/Z-12 by irrigation of Z compounds and intratumoral injection of TNFa. In MCF-7 bearing mice, TNFa/Z-12 combination induced significant suppression of tumor growth when compared with vehicle, Z-12, and TNFa (Fig. 6H ). The pronounced delay in tumor growth, especially by the treatment of TNFa/Z-12 combination, was translated into tumor weight values, which was obtained at the end of the treatment (Fig. 6I ). Tumor growth inhibition and extensive apoptosis of cancer cells were also observed when mice were treated with Z-10 or Z-12 alone (Fig. 6H and I and Supplementary Fig. S6H-S6J ), likely due to the self-produced TNFa of tumor tissues.
Discussion
By using a variety of in vitro and in vivo approaches, we showed that several nitrostyrene derivatives could bind to RXRa through a new mechanism ( Fig. 2 and 3 and Supplementary  Figs. S2 and S3 ). It has been reported that synthetic nitro compounds T0070907 and GW9662 are PPARg antagonists (28) . Endogenous nitro-fatty acids, including nitrated linoleic acid (LA-NO 2 ) and nitrated oleic acid (OA-NO 2 ), are also identified as robust PPARg agonists, which induce PPARgdependent effects, including macrophage CD-36 expression, adipocyte differentiation, and glucose uptake (29, 30) . Several other nuclear receptors, such as ER and HNF4a, were also found to bind to nitro compounds (31, 32) . However, to our knowledge, Z compounds are the first identified nitro ligands for RXRa. Because the variety of the nitrated lipid acids and other nitrated small molecules exist in the body (33) , it is much likely there are endogenous nitro ligands of RXRa, which is worthy of further investigation.
It has been reported that a replacement of nitro group with carboxyl group abolishes the effects of nitrostyrene derivatives on proapoptotic induction (34), antiplatelet activity, and inhibiting NLRP3 inflammasome activation (35, 36) . Here, we also dem-onstrated that nitro group was essential for Z compounds to bind to RXRa ( Fig. 2A and Supplementary Fig. S2 ), stimulate RXRa transactivation ( Fig. 2D and E) , regulate RXRa oligomerization ( Fig. 3B and Supplementary Fig. S3A ), inhibit TNFa activation of NF-kB ( Supplementary Fig. S4F) , and induce cancer cell apoptosis ( Supplementary Fig. S6E ). Therefore, nitro group is critical for the nitrostyrene derivatives to exert their wide biologic activities, which is partly due to the requirement of nitro group for nitrostyrene derivatives binding to RXRa ( Fig. 2 and Supplementary Fig. S2 ).
Crystallographic analysis indicates that amino acid residues responsible for interacting with LA-NO 2 and rosiglitazone are different, leading to distinct conformational changes of PPARg-LBD when complexed with LA-NO 2 and rosiglitazone (37) . Similarly, Z compounds induced distinct conformations of RXRa homodimer (Fig. 3B and C and Supplementary Fig.  S3A and S3B ). Our mutagenesis study indicated that Cys432, which is located at the corner of the L shape LBP (13, 38) , was essential for Z compounds to activate and bind to RXRa ( Fig. 3E and Supplementary Fig. S3C and S3D) . The distinct conformations of RXRa induced by Z compounds may rely on their unique interaction with Cys432, which was in part supported by the self-activation of RXRa mutants C432Y and C432W mimic the binding of Z compounds ( Fig. 3E-H) . The importance of Cys432 for specific ligand binding and activity has been illustrated by an early report. Tributyltin, an organotin compound, is able to induce an active conformation of RXRa-LBD, primarily due to the covalent bond formed between tin atom and Cys432 (39) .
Crystallographic analysis demonstrates that hydrogen bonds formed between nitro group and residues Arg288 or Glu343 stabilize the complex of LA-NO 2 and PPARg (37), while spectrometric analysis indicates that OA-NO 2 covalent binds PPARg by Michael addition of Cys285 with nitroalkene (40) . Our SPR results showed the quick dissociation of Z compounds from RXRa-LBD in the dissociation phase (Fig. 2B) , implying no strong covalent binding between Z compounds and RXRa. However, we could not exclude the possibility that Z compounds bind to RXRa through a weak covalent binding via the Michael addition of Cys432 with nitroalkene, which might be microenvironment-sensitive (in RXRa LBP) and reversible referring to the nitroalkylation reactions (41) .
tRXRa is able to bind to p85a to enhance TNFa-stimulated Akt activation and cancer growth (20) . In this study, we showed that tRXRa could also enhance TNFa activation of the NF-kB signaling probably through its interaction with TRAF2 and induction of RIP1 ubiquitination ( Fig. 5 and Supplementary  Fig. S5 ). Interestingly, TNFa promoted the interaction of TRAF2 with tRXRa but not RXRa (Fig. 5D and F and Supplementary Fig. S5C and D) , suggesting a possible mechanism by which abnormal activation of the TNFa/NFkB pathway plays a role in mediating the tumor-promoting effect of tRXRa that is specifically produced in cancer cells (15, 20) . Such a tRXRamediated activation of the NF-kB pathway may provide a new direction for targeting tRXRa through inhibiting its interactions with TRAF2. Indeed, our data showed that Z compounds strongly inhibited TNFa-induced interaction of TRAF2 with tRXRa and RIP1 ubiquitination ( Fig. 5E and F) , which was associated with their inhibition of the TNFa/NFkB signaling pathway in a tRXRa-dependent manner (Fig. 4D and E and Supplementary Fig. S4D ). Unlike sulindac and its derivatives (20) , Z compounds did not inhibit tRXRa interaction with p85a ( Supplementary Fig. S4A ), reflecting the different tRXRa conformations induced by nitrostyrene derivatives and sulindac derivatives.
Suppression of the TNFa/NFkB signaling pathway may convert TNFa from a tumor promoter to a tumor suppressor (42, 43) . Indeed, the potent effects of Z compounds on inhibiting the TNFa/NFkB survival pathway resulted in a synergistic effect of Z compounds and TNFa on inducing tumor cell apoptosis ( Fig. 6 and Supplementary Fig. S6 ), likely due to the activation of the TNFa-mediated pathway of apoptosis ( Fig.  6A and Supplementary Fig. S6B ). The synergistic antitumor effect of the combination was tRXRa dependent (Fig. 6C-E and Supplementary Fig. S6D ), consistent with the facts that Z compounds bound to RXRa and inhibited TNFa activation of NF-kB in a tRXRa-dependent manner. Thus, our results define a class of compounds that could convert TNFa signaling from survival to death in cancer cells by targeting the tRXRa-mediated TNFa/NFkB signaling pathway.
Generally, the molecular weight of RXRa ligands ranges from 300 to 500 Da determined by the effective binding and spatial size of RXRa-LBP (2, 11) . The sizes of Z compounds (Z-10, 199 Da; Z-12, 249 Da) are relatively small and it was imagined that Z compounds only partially occupied RXRa-LBP, which might also explain that the binding affinity of Z compounds fall into the mmol/L but not nmol/L range. However, the mmol/L working concentrations of Z compounds for binding to RXRa, inducing RXRa conformational changes, inhibiting TNFa activation of NF-kB, and promoting cancer cell apoptosis were in the same order of magnitude, reflecting the relevance of their binding to RXRa and their tRXRa-dependent physiologic functions. The small size of Z compounds also makes it possible to optimize them. One of the optimizing approaches is to increase their molecular sizes to enhance the van der Waal interactions between Z compounds and the LBP of RXRa, and the other one is to introduce a carboxyl group in appropriate positions of Z compounds to interact with Arg316, referring to the molecular basis of the interaction between LA-NO 2 and PPARg-LBD (37) .
Taken together, our results identify the first nitro ligands of RXRa with unique RXRa-binding mode and tRXRa-dependent abilities of anti-NF-kB activation and proapoptosis of cancer cells. Our results also reveal a new mechanism by which tRXRa promotes tumor growth, providing a new strategy for inhibiting TNFa activation of the NF-kB pathway by targeting tRXRa.
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